Search
Enprofylline
go.drugbank.com/drugs/DB00824ApprovedWithdrawnEnprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and ...
Protein phosphatase 3 catalytic subunit alpha
go.drugbank.com/bio_entities/BE0004238TargetHumansPositively regulates the CACNA1B/CAV2.2-mediated Ca(2+) release probability at hippocampal neuronal soma and synaptic terminals (By similarity). … In response to increased Ca(2+) levels, dephosphorylates and activates phosphatase SSH1 which results in cofilin dephosphorylation (PubMed:15671020).
Synonyms: CAM-PRP catalytic subunitGaboxadol
go.drugbank.com/drugs/DB06554InvestigationalIt acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing
Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalTraditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.
Satricabtagene autoleucel
go.drugbank.com/drugs/DB18288InvestigationalSatricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalThe AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
Pinacidil
go.drugbank.com/drugs/DB06762ApprovedThis drug has been discontinued by the FDA. … Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance.
Nafamostat
go.drugbank.com/drugs/DB12598InvestigationalThe use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
Caviar, unspecified
go.drugbank.com/drugs/DB14241ApprovedCaviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.